focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
As we age, or suffer from different health conditions, we are offered a combination of drugs and preventive treatments such as the annual flue jab.
If Doxorubicin, using Avacta AVA6000, can be offered with a minimal risk, could there be an option to offer it as a preventative treatment? An annual dose to treat early stage cancers before the individual shows symptoms.
Early treatment could save lives and save £m’s in more intensive NHS treatments.
Just a Sunday morning thought,...
Difficult few days for the markets and also the AVACTA share price.
AGM with us on Thursday so the possibility of several RNS next week
While the share price is down, there seems to be a distinct lack of green boxes today.
Gone to spread their thoughts somewhere else?
Good to read some interesting content and points of view. Let’s see what Thursday brings.
GLA
https://www.lse.co.uk/ShareShortPositions.asp?shareprice=AVCT&share=Avacta
@MCB55
Hargreaves Lansdown holds a significant number of shares and a large proportion will be private investors in SIPP’s, ISA and other products.
Take your point that an acquisition requires 51% of shareholders to be receptive, however, this would have to offer a return that reflects the levels of investment made and the long term opportunity.
“Anything like £1 or less then any such silly bids would be unsuccessful!!”
I think we are in agreement?
Current share price puts Avacta market cap around £ 115m.
Avacta has cash in the bank (estimate £ 20m).
With the current share price, Avacta could be acquired for £ 95m (£ 115m - £ 20m).
Not a large amount to pay for 10 years of R&D and some very innovative science.
However
An acquisition requires 51%+ shares and acquiring 126,000,000 shares will push the share price up. Any bid should reflect the Avacta high (£ 2.90 in March 2021) along with the IP opportunity.
It is a possibility but suspect the big pharma’s will be watching technical updates over the next few months before making any offer(s). If they wait too long, perhaps a bidding war?
@Ripley
Would you mind is we drop the word “IF” from this thread?
AVA6000 is in clinical trials. Dosing started at 80mg/m2 and the RNS from 3rd February stated that Avacta will increase the dose to 120mg/m2. The dosage is an increase on the standard implying that AVA6000 is already successful.
https://avacta.com/avacta-announces-dose-escalation-in-the-phase-i-clinical-study-of-ava6000-pro-doxorubicin/
HOW successful will AVA6000 be?
Increasing the dose from 120mg/m2 to 160mg/m2 or 200 mg/m2 will reduce the number of treatments and improve patient outcomes. AVA6000 will reduce side effects and be live saving. On it’s own, AVA6000 is worth more than the current market cap.
I have been here for 9 years so am happy to wait another 12 months for the game changing news.
As ever, DYOR and GLA
The Diagnostics Division remains busy.
Working on LFT and other new products?
Assay Development Scientist / Senior Assay Development Scientist, IVD
Product Development Manager, IVD
Quality Assurance Officer
Regulatory Affairs Officer
@Bella6532
Some people make things for a living.
Some people educate or save lives.
Most people contribute to society.
Thank you for bringing Jupiter’s shorting activities to everyone’s attention.
https://shorteurope.com/history_player.php?player=JUPITER%20INVESTMENT%20MANAGEMENT%20LIMITED&land=united_kingdom
I have purchased Jupiter products in the past but based on what I am reading on ShortEurope.com, I will never recommend or use their services again. They may be making money, but where are the ethics?
Boots the Chemist has announced that it will start to sell single and multi-pack LFT’s.
As HM Government has decided to remove free LFT’s, perhaps an opportunity for Avacta & Medusa 19?
Can Avacta bring the LFT to market soon?
Jupiter took a hit on Synairgen this week. Sorry for SNG holders but Jupiter, and other shorters, got what they deserved.
Not imminent, but wouldn’t we all love a killer RNS from Avacta at 07:00 tomorrow?
I have been invested in Avacta since 2013 when the main products were:
- Optim 1000 (drug development)
- AX-1 (blood tests)
- Aptuscan (acquired by Avacta in 2012)
It has been a long term investment which I have added to over time.
AS holds 431,000 Avacta shares.
At £ 2.90 = £ 1,25m
At £ 0.46 = £ 198K
Paper Loss > £ 1m
If AS did not have confidence in his scientific team and the major releases due in both the short and long term, perhaps he would have sold more shares when he bought his new home or when the share price was at it's highest?
When the science is shown to work, Avacta will be life changing in many ways.
It is difficult at the moment but, those who sold in a panic may regret their decision.
Some will disagree, I know.
As ever, DYOR and GLA
Avacta share price dropped from a high (£ 2.90) to the current levels (£ 0.50). The delay and suspension of the LFT was contributing.
Synairgen has had a hard RNS this morning and gone from £ 1.70 to £ 0.11 but is starting to rise. Currently around £ 0.25.
Having experienced the 12 month drops with Avacta, LTH’s can genuinely empathise with those holding Synairgen.
We are fortunate at Avacta that we have multiple products either in development or with business partners. There will still be a need for LFT’s and our own LFT may make a return soon. The initial AVA6000 results are positive and the science is life saving and game changing. Other LTH’s can add to the list of opportunities.
To the LTH’s at Synairgen, hopefully there will be positive news to follow. GLA.
To those holding Avacta, do not make a knee jerk decision. Stay with the science and the positive news will follow in the coming months.
As ever, GLA and DYOR
@Valueinv
Shares in issue at 151m.
Click on the link and scroll down:
https://www.investing.com/equities/avacta-group-plc